Boone Capital Management LLC
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 17, 2026), Boone Capital Management LLC reported 15 stock positions worth $318.6 million. Its top holding was Medtronic (MDT) at 12.9% of the portfolio, followed by Mirum Pharmaceuticals (MIRM, 10.4%) and Ionis Pharmaceuticals (IONS, 10.4%). Compared with Q3 2025, it opened 4 new positions, sold out of 5, added to 4 and reduced 5. The biggest buy was a new position in Astrazeneca PLC-Spons ADR (AZN) and the biggest sale an exit from Icon (ICLR).
- Most Recent 13F
- Q2 2026
- Location
- ATLANTA, GA
- CIK
- 0001882053
- Portfolio Value
- $318.6M (Q4 2025)
- SEC Filing
- 0001214659-26-001960 ↗ filed Feb 17, 2026
Holdings Value
Holdings 15 stocks · $318.6M
| MDT Medtronic PLC | 12.93% | 428,789 | $41.2M | No change |
| MIRM Mirum Pharmaceuticals Inc. | 10.44% | 421,236 | $33.3M | Reduce -21.4% |
| IONS Ionis Pharmaceuticals Inc. | 10.37% | 417,833 | $33.1M | No change |
| CI The Cigna Group | 8.33% | 96,453 | $26.5M | Add +16.3% |
| BMRN Biomarin Pharmaceutical Inc. | 7.68% | 411,880 | $24.5M | Add +25.4% |
| NBIX Neurocrine Biosciences Inc. | 6.76% | 151,815 | $21.5M | Reduce -8.8% |
| UNH Unitedhealth Group Inc. | 6.40% | 61,762 | $20.4M | Add +6.3% |
| AZN Astrazeneca PLC-Spons ADR | 6.35% | 220,201 | $20.2M | New |
| HQY Healthequity Inc. | 6.12% | 212,856 | $19.5M | New |
| LIVN Livanova PLC | 5.58% | 288,895 | $17.8M | Add +72.0% |
| RAPT Rapt Therapeutics Inc. | 5.00% | 470,456 | $15.9M | Reduce -39.9% |
| BBIO Bridgebio Pharma Inc. | 4.44% | 184,963 | $14.1M | Reduce -59.8% |
| KOD Kodiak Sciences Inc. | 4.42% | 503,830 | $14.1M | Reduce -29.6% |
| TYRA Tyra Biosciences Inc. | 3.29% | 398,482 | $10.5M | New |
| WVE Wave Life Sciences Ltd. | 1.88% | 352,144 | $6.0M | New |
Portfolio Sells Q3 2025 → Q4 2025
| ICLR Icon PLC | Sold out | 0.00% | −5.50 |
| COGT Cogent Biosciences Inc. | Sold out | 0.00% | −4.45 |
| BBIO Bridgebio Pharma Inc. | Reduce -59.8% | 4.44% | −3.40 |
| QURE Uniqure NV | Sold out | 0.00% | −2.82 |
| MIRM Mirum Pharmaceuticals Inc. | Reduce -21.4% | 10.44% | −2.44 |
| CLPT Clearpoint Neuro Inc. | Sold out | 0.00% | −2.03 |
| RAPT Rapt Therapeutics Inc. | Reduce -39.9% | 5.00% | −1.62 |
| NBIX Neurocrine Biosciences Inc. | Reduce -8.8% | 6.76% | −0.90 |
| ABEO Abeona Therapeutics Inc. | Sold out | 0.00% | −0.87 |
| KOD Kodiak Sciences Inc. | Reduce -29.6% | 4.42% | +0.58 |
Portfolio Buys Q3 2025 → Q4 2025
| AZN Astrazeneca PLC-Spons ADR | New | 6.35% | +6.35 |
| HQY Healthequity Inc. | New | 6.12% | +6.12 |
| TYRA Tyra Biosciences Inc. | New | 3.29% | +3.29 |
| LIVN Livanova PLC | Add +72.0% | 5.58% | +2.69 |
| WVE Wave Life Sciences Ltd. | New | 1.88% | +1.88 |
| BMRN Biomarin Pharmaceutical Inc. | Add +25.4% | 7.68% | +1.85 |
| CI The Cigna Group | Add +16.3% | 8.33% | +0.49 |
| UNH Unitedhealth Group Inc. | Add +6.3% | 6.40% | −0.18 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 16 | $427.5M | TFX, MIRM, CI, IONS, UNH |
| Q1 2026 | 13 | $326.4M | MIRM, IONS, CI, MDT, TFX |
| Q4 2025 | 15 | $318.6M | MDT, MIRM, IONS, CI, BMRN |
| Q3 2025 | 16 | $305.0M | MDT, MIRM, IONS, CI, BBIO |
| Q2 2025 | 11 | $233.2M | MDT, MIRM, BMRN, AVTR, UNM |
| Q1 2025 | 12 | $293.8M | UNM, MDT, MIRM, GMED, CI |
| Q4 2024 | 13 | $296.5M | UNM, GMED, PRGO, MIRM, MOH |
| Q3 2024 | 17 | $385.8M | UNM, GMED, CI, MOH, CHE |
| Q2 2024 | 19 | $383.4M | UNM, GMED, CI, MOH, DHR |
| Q1 2024 | 21 | $494.4M | UNM, CI, MOH, ENOV, BAX |